TRCT
CYAD

Tower Research Capital (TRC)’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Tower Research Capital (TRC)’s Portfolio CYAD Stock Details CYAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,225
Closed -$4K – 6893
2021
Q4 		$4K Buy
+1,225
New +$5.15K ﹤0.01% 5380
2019
Q3 		– Sell
-1
Closed – – 4661
2019
Q2 		$0 Sell
1
-39
-98% -$744 ﹤0.01% 4500
2019
Q1 		$1K Sell
40
-67
-63% -$1.43K ﹤0.01% 3661
2018
Q4 		$2K Buy
+107
New +$2.58K ﹤0.01% 3472
2018
Q2 		– Sell
-32
Closed -$1K – 4206
2018
Q1 		$1K Sell
32
-116
-78% -$4.82K ﹤0.01% 3123
2017
Q4 		$6K Buy
148
+119
+410% +$5.95K ﹤0.01% 2839
2017
Q3 		$2K Buy
29
+9
+45% +$404 ﹤0.01% 3607
2017
Q2 		$1K Sell
20
-337
-94% -$13.3K ﹤0.01% 2540
2017
Q1 		$9K Buy
357
+10
+3% +$218 ﹤0.01% 1879
2016
Q4 		$7K Buy
347
+29
+9% +$551 ﹤0.01% 2891
2016
Q3 		$8K Hold
318
– – ﹤0.01% 2249
2016
Q2 		$8K Hold
318
– – ﹤0.01% 3055
2016
Q1 		$14K Buy
318
+313
+6,260% +$12.8K ﹤0.01% 1650
2015
Q4 		$0 Sell
5
-57
-92% -$2.51K ﹤0.01% 5218
2015
Q3 		$3K Sell
62
-721
-92% -$37.1K ﹤0.01% 3197
2015
Q2 		$41K Buy
+783
New +$42.1K ﹤0.01% 1534

Other funds holding CYAD

FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Tower Research Capital (TRC)'s CYAD Position: Q1 2022 in Review

Tower Research Capital (TRC) sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q1 2022, closing a stake of 1,225 shares — an estimated $4K sold.

Tower Research Capital (TRC) first reported a position in CYAD in Q2 2015 and held it in 16 quarters. The position peaked at $41K in Q2 2015. 8 funds tracked by Wall St. Rank hold CYAD as of Q1 2022.

  • Tower Research Capital (TRC) reported no remaining Celyad Oncology SA American Depositary Shares position as of Q1 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,225 Celyad Oncology SA American Depositary Shares shares in Q1 2022, an estimated $4K.
  • Tower Research Capital (TRC) first reported a position in Celyad Oncology SA American Depositary Shares in Q2 2015 and held it in 16 quarters.
  • Tower Research Capital (TRC)'s Celyad Oncology SA American Depositary Shares position peaked at $41K in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q1 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2022, filed 12 May 2022.